Insiders EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Real-time Estimate Cboe BZX Other stock markets 01:19:32 2024-06-06 pm EDT			5-day change	1st Jan Change
9.43 ^USD	-3.68%		-12.47%	-59.28%

Jun. 04	JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating	MT
May. 08	Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EyePoint Pharmaceuticals, Inc. Expands Scientific Advisory Board	Apr. 02	CI
EyePoint Pharmaceuticals Names Ramiro Ribeiro Chief Medical Officer	Mar. 04	MT
EyePoint Pharmaceuticals, Inc. Announces Executive Changes	Mar. 04	CI
Eyepoint Pharmaceuticals Insider Sold Shares Worth $1,265,539, According to a Recent SEC Filing	Jan. 30	MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $660,370, According to a Recent SEC Filing	Jan. 29	MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $297,621, According to a Recent SEC Filing	Jan. 26	MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $409,790, According to a Recent SEC Filing	Jan. 26	MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $795,191, According to a Recent SEC Filing	Jan. 24	MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $484,124, According to a Recent SEC Filing	Jan. 10	MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing	Dec. 08	MT
EyePoint Pharmaceuticals Insider Sold Shares Worth $19,510,637, According to a Recent SEC Filing	Dec. 08	MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $990,000, According to a Recent SEC Filing	Dec. 06	MT
Eyepoint Pharmaceuticals Insider Sold Shares Worth $415,200, According to a Recent SEC Filing	Dec. 06	MT
EyePoint Pharmaceuticals, Inc. Announces Executive Changes	23-10-16	CI
Akari Therapeutics Names Wendy DiCicco Interim Finance Chief	23-07-19	MT
EyePoint Pharmaceuticals Names Jay Duker CEO; Shares Climb	23-07-10	MT
EyePoint Pharmaceuticals Names Jay Duker CEO	23-07-10	MT
Eyepoint Pharmaceuticals, Inc. Announces Chief Executive Officer Changes	23-07-10	CI
Eyepoint Pharmaceuticals, Inc. Announces Executive Changes	23-07-10	CI
Eyepoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer	23-01-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders EyePoint Pharmaceuticals, Inc.

Equities

EYPT

US30233G2093

Insiders

Filters